CONMED Corporation

NYSE:CNMD Stok Raporu

Piyasa değeri: US$1.1b

CONMED Gelecekteki Büyüme

Future kriter kontrolleri 3/6

CONMED kazanç ve gelirin sırasıyla yıllık 30.8% ve 3.8% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 31.6% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 11.3% olacağı tahmin edilmektedir.

Anahtar bilgiler

30.8%

Kazanç büyüme oranı

31.63%

EPS büyüme oranı

Medical Equipment kazanç büyümesi16.1%
Gelir büyüme oranı3.8%
Gelecekteki özkaynak getirisi11.32%
Analist kapsamı

Good

Son güncelleme18 May 2026

Gelecekteki son büyüme güncellemeleri

Recent updates

Anlatı Güncellemesi • May 20

CNMD: Execution And Margin Stability Will Be Tested In Medtech Reset

Analysts have reduced CONMED's fair value estimate and price target to $40 from $52. They cite a reset in medtech valuations, concerns around product cycles and utilization, and a lower assumed future P/E multiple, while keeping revenue growth and profit margin assumptions broadly steady.
Anlatı Güncellemesi • May 01

CNMD: Execution Repairs And Margin Stability Will Support Future Upside

Narrative Update Overview Analysts have trimmed their average price targets on CONMED by $3, alongside neutral ratings and concerns around product execution and a lack of near term catalysts, even as updated assumptions reflect steady revenue growth, profit margins around 10.8% and a slightly lower future P/E multiple. Analyst Commentary Recent research on CONMED has centered on valuation reset, execution around key products, and the search for clear catalysts, with JPMorgan trimming its price target by $3 and other firms shifting to more neutral stances.
Anlatı Güncellemesi • Apr 17

CNMD: Execution Questions And Limited Catalysts Will Shape Balanced Risk Profile

Analysts have reset their price target on CONMED to $39, trimming it by $16 from the prior $55. They cite concerns around AirSeal competition, recent execution issues, and a lack of clear near term catalysts for a turnaround in sentiment.
Anlatı Güncellemesi • Apr 02

CNMD: Execution Rebound And Margin Focus Will Support Future Upside

The analyst price target for CONMED has been reduced by $3 to $52, as analysts factor in a slightly higher discount rate and a lower future P/E multiple while still modeling modestly higher revenue growth and profit margins, and acknowledging recent downgrades that highlight concerns around execution and a lack of near term catalysts. Analyst Commentary Recent research on CONMED reflects a mixed setup, with some analysts focused on execution risks and a lack of clear near term catalysts, while others maintain a more balanced stance that supports a mid range valuation and steady expectations.
Anlatı Güncellemesi • Mar 18

CNMD: Execution Concerns And Leadership Transition Will Shape Balanced Risk Profile

Narrative Update: CONMED Price Target Shift The analyst price target for CONMED has been revised from $42 to $39, with analysts pointing to execution missteps, weaker sentiment around the AirSeal product, and a lack of clear near term catalysts as key reasons for the adjustment. Analyst Commentary Recent Street research on CONMED has tilted more cautious, with several bearish analysts highlighting execution risk, questions around AirSeal, and a limited near term catalyst path to re-rate the shares.
Anlatı Güncellemesi • Mar 04

CNMD: Portfolio Refocus And Leadership Change Will Shape Balanced Risk Profile

Narrative Update on CONMED Analysts kept their $42 price target for CONMED unchanged. They cited slightly higher assumed revenue growth and profit margins along with a modestly lower discount rate and future P/E, which together support a steady valuation view despite ongoing sector volatility highlighted in recent research.
Anlatı Güncellemesi • Feb 17

CNMD: Portfolio Refocus And Higher Future P/E Will Support Returns

Analysts maintained their fair value estimate for CONMED at $55.00 and refreshed their price target framework to incorporate more conservative assumptions for revenue growth and profit margins, while also reflecting a higher future P/E multiple. Analyst Commentary Bullish analysts appear comfortable holding their US$55.00 fair value estimate for CONMED while updating models to reflect more conservative assumptions for revenue growth and margins.
Anlatı Güncellemesi • Feb 03

CNMD: Future Portfolio Shift And Capital Moves Signal Balanced Risk Profile

Analysts have reduced their price target on CONMED to US$42 from US$55, citing a higher discount rate, more conservative revenue growth assumptions, improved profit margin expectations, and a lower future P/E multiple in their updated models. Analyst Commentary Bearish analysts are using the lower US$42 price target as a signal that they see less room for upside in CONMED at current levels, especially when they factor in higher discount rates and more cautious revenue assumptions.
Anlatı Güncellemesi • Jan 19

CNMD: Gastro Exit And Buybacks Will Support Future Margin Expansion

Analysts modestly adjusted their price target for CONMED, citing a slightly lower discount rate, unchanged fair value of $48.40, and minimal tweaks to long term growth and P/E assumptions that together fine tune their outlook rather than overhaul it. Analyst Commentary Bullish Takeaways Bullish analysts see the steady fair value estimate of $48.40, together with the slightly lower discount rate, as a sign that their view on CONMED’s risk profile and long term earnings power remains intact even after recent fine tuning.
Anlatı Güncellemesi • Jan 05

CNMD: Gastro Exit And Buybacks Will Support Margin Expansion Ahead

Analysts have trimmed their price target for CONMED to about US$48.40 from roughly US$54.00, pointing to slightly lower growth assumptions and a reduced future P/E multiple, partly balanced by a marginally higher profit margin outlook. What's in the News CONMED plans to exit its gastroenterology product lines, aiming to focus resources on core areas such as minimally invasive, robotic and laparoscopic surgery, smoke evacuation, and orthopedic soft tissue repair (Key Developments).
Anlatı Güncellemesi • Dec 20

CNMD: Focused Surgical Portfolio And Buybacks Will Support Stronger Future Returns

Analysts have lowered their price target on CONMED from 80.00 dollars to 55.00 dollars, citing slightly slower expected revenue growth and a higher discount rate that more than offset improved margin and valuation assumptions. What's in the News CONMED will exit its gastroenterology product lines to focus resources on core areas including minimally invasive, robotic, and laparoscopic surgery, smoke evacuation, and orthopedic soft tissue repair.
Seeking Alpha • Dec 15

Conmed Taking On More Pain In The Pursuit Of Future Gain

Summary Conmed (CNMD) shares are nearing decade lows despite credible progress with supply issues and ongoing efforts to shift toward higher-growth, higher-margin products. Management accelerated the exit from the lower-margin gastroenterology business, trading near-term revenue and EPS dilution for an 80bp margin boost and improved strategic focus. AirSeal's attach rate remains pressured by Intuitive Surgical's dv5, but upside exists from non-robotic procedures and OUS and ACS market expansion. CNMD appears undervalued on DCF and EV/revenue, but lacks near-term growth catalysts and remains a high-risk value play pending tangible restructuring results. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Dec 06

CNMD: Margin Expansion And Buyback Program Will Drive Strong Future Returns

Analysts have nudged their price target on CONMED slightly higher to $54, citing modestly lower discount rate and revenue growth assumptions, offset by a slightly improved profit margin outlook and a marginally lower future P/E multiple that together support a stable valuation profile. Analyst Commentary Analyst views on CONMED remain balanced, with recent model tweaks reflecting a more nuanced outlook on growth, profitability, and valuation.
Anlatı Güncellemesi • Nov 22

CNMD: Margin Initiatives And Robust Buyback Will Drive Long-Term Shareholder Value

CONMED's analyst price target has been reduced from $56 to $54 per share, as analysts cite modest cuts to growth and profit outlooks, along with slightly higher discount rates following recent sector updates. Analyst Commentary Analysts have provided a range of perspectives on CONMED’s outlook based on recent developments in company performance and sector trends.
Anlatı Güncellemesi • Nov 07

CNMD: Improving Profit Margins And Robust Buyback Program Will Drive Shareholder Value

CONMED's analyst price target has been lowered from $61 to $56. This change reflects a more cautious stance as analysts point to expectations of slower revenue growth and a higher discount rate, despite improvements in underlying profit margins and future valuation multiples.
Analiz Makalesi • Oct 06

These 4 Measures Indicate That CONMED (NYSE:CNMD) Is Using Debt Reasonably Well

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analiz Makalesi • Sep 12

CONMED (NYSE:CNMD) Has Announced A Dividend Of $0.20

CONMED Corporation ( NYSE:CNMD ) has announced that it will pay a dividend of $0.20 per share on the 3rd of October...
Analiz Makalesi • Aug 08

CONMED's (NYSE:CNMD) Solid Profits Have Weak Fundamentals

CONMED Corporation ( NYSE:CNMD ) just reported some strong earnings, and the market reacted accordingly with a healthy...
Analiz Makalesi • Jul 03

Are Investors Undervaluing CONMED Corporation (NYSE:CNMD) By 49%?

Key Insights Using the 2 Stage Free Cash Flow to Equity, CONMED fair value estimate is US$107 Current share price of...
Analiz Makalesi • May 24

CONMED (NYSE:CNMD) Is Paying Out A Dividend Of $0.20

CONMED Corporation ( NYSE:CNMD ) will pay a dividend of $0.20 on the 3rd of July. This means the dividend yield will be...
Analiz Makalesi • May 17

CONMED Corporation's (NYSE:CNMD) Shares Bounce 26% But Its Business Still Trails The Market

Those holding CONMED Corporation ( NYSE:CNMD ) shares would be relieved that the share price has rebounded 26% in the...
Analiz Makalesi • Mar 31

Is CONMED (NYSE:CNMD) Using Too Much Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Seeking Alpha • Feb 28

Repeated Disappointments On Growth And Margins Leaves Conmed Even Deeper In The Doghouse

Summary Conmed's ambitious revenue growth targets and ongoing operational issues have led to underperformance, with shares down 10% since my last update and ongoing concerns about growth, margins, and tariffs. Despite a decent Q4, Conmed's 2025 guidance was disappointing, with no margin expansion expected and a need to remediate supply and inventory issues. The threatened 25% tariff on goods imported from Mexico could severely affect earnings, adding to the company's existing operational and competitive challenges. While Conmed's valuation appears undemanding, significant risks and uncertainties suggest it may be prudent to wait for clearer signs of improvement before investing. Read the full article on Seeking Alpha
Analiz Makalesi • Feb 28

CONMED (NYSE:CNMD) Is Paying Out A Dividend Of $0.20

CONMED Corporation ( NYSE:CNMD ) will pay a dividend of $0.20 on the 4th of April. This means the dividend yield will...
Analiz Makalesi • Feb 08

CONMED Corporation Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Shareholders might have noticed that CONMED Corporation ( NYSE:CNMD ) filed its full-year result this time last week...
Analiz Makalesi • Jan 20

CONMED Corporation (NYSE:CNMD) Looks Inexpensive But Perhaps Not Attractive Enough

When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 19x, you may...
Analiz Makalesi • Jan 01

Is Now The Time To Look At Buying CONMED Corporation (NYSE:CNMD)?

CONMED Corporation ( NYSE:CNMD ), might not be a large cap stock, but it saw a decent share price growth of 11% on the...
Analiz Makalesi • Dec 13

CONMED (NYSE:CNMD) Has Affirmed Its Dividend Of $0.20

The board of CONMED Corporation ( NYSE:CNMD ) has announced that it will pay a dividend on the 3rd of January, with...
Analiz Makalesi • Nov 25

Does CONMED (NYSE:CNMD) Have A Healthy Balance Sheet?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Analiz Makalesi • Nov 07

CONMED's (NYSE:CNMD) Earnings Are Weaker Than They Seem

Unsurprisingly, CONMED Corporation's ( NYSE:CNMD ) stock price was strong on the back of its healthy earnings report...
Analiz Makalesi • Nov 02

Earnings Beat: CONMED Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

It's been a pretty great week for CONMED Corporation ( NYSE:CNMD ) shareholders, with its shares surging 13% to...

Kazanç ve Gelir Büyüme Tahminleri

NYSE:CNMD - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/20281,514154N/A1744
12/31/20271,4361401731626
12/31/20261,3621201951956
3/31/20261,37155124143N/A
12/31/20251,37547151171N/A
9/30/20251,34764149168N/A
6/30/20251,326110148165N/A
3/31/20251,316119165179N/A
12/31/20241,307132154167N/A
9/30/20241,288132166180N/A
6/30/20241,27699159175N/A
3/31/20241,26282142158N/A
12/31/20231,24564106125N/A
9/30/20231,169583857N/A
6/30/20231,139881637N/A
3/31/20231,099-94729N/A
12/31/20221,045-811233N/A
9/30/20221,069-835979N/A
6/30/20221,042-1145674N/A
3/31/20221,020687490N/A
12/31/20211,0116397112N/A
9/30/2021989628398N/A
6/30/20219795499112N/A
3/31/2021881137083N/A
12/31/2020862105265N/A
9/30/202087406985N/A
6/30/202087006987N/A
3/31/20209513484103N/A
12/31/201995529N/A95N/A
9/30/201993329N/A79N/A
6/30/201990128N/A47N/A
3/31/201987631N/A46N/A
12/31/201886041N/A75N/A
9/30/201884072N/A71N/A
6/30/201882873N/A80N/A
3/31/201881271N/A75N/A
12/31/201779655N/A66N/A
9/30/201777815N/A58N/A
6/30/201777316N/A70N/A
3/31/201776912N/A72N/A
12/31/201676415N/A40N/A
9/30/201675016N/A36N/A
6/30/201673517N/A24N/A
3/31/201672222N/A17N/A
12/31/201571930N/A51N/A
9/30/201572334N/A64N/A
6/30/201572927N/A65N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: CNMD 'nin tahmini kazanç büyümesi (yıllık 30.8% ) tasarruf oranının ( 3.5% ) üzerindedir.

Kazançlar ve Piyasa: CNMD şirketinin kazançlarının (yıllık 30.8% ) US pazarından (yıllık 16.7% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: CNMD şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: CNMD şirketinin gelirinin (yıllık 3.8% ) US pazarından (yıllık 11.7% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: CNMD şirketinin gelirinin (yıllık 3.8% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: CNMD 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 11.3 %).

Büyüyen şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/21 20:37
Gün Sonu Hisse Fiyatı2026/05/21 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

CONMED Corporation 16 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Travis SteedBarclays
Travis SteedBofA Global Research
Travis SteedBofA Global Research